Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Insider Camille L. Bedrosian Sells 12,425 Shares

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Get Free Report) insider Camille L. Bedrosian sold 12,425 shares of the business's stock in a transaction that occurred on Monday, March 31st. The stock was sold at an average price of $3.47, for a total value of $43,114.75. Following the completion of the sale, the insider now owns 194,375 shares of the company's stock, valued at approximately $674,481.25. This trade represents a 6.01 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Amylyx Pharmaceuticals Price Performance

Shares of Amylyx Pharmaceuticals stock traded up $0.03 during midday trading on Monday, hitting $3.46. The company had a trading volume of 1,168,275 shares, compared to its average volume of 1,347,684. Amylyx Pharmaceuticals, Inc. has a 1-year low of $1.58 and a 1-year high of $7.27. The business's 50 day simple moving average is $3.55 and its two-hundred day simple moving average is $4.07. The stock has a market cap of $306.56 million, a PE ratio of -0.91 and a beta of -0.53.

Amylyx Pharmaceuticals (NASDAQ:AMLX - Get Free Report) last posted its quarterly earnings data on Tuesday, March 4th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by ($0.06). The firm had revenue of ($0.67) million for the quarter. On average, sell-side analysts expect that Amylyx Pharmaceuticals, Inc. will post -2.2 EPS for the current fiscal year.

Remove Ads

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on AMLX shares. Mizuho upgraded shares of Amylyx Pharmaceuticals from a "neutral" rating to an "outperform" rating and boosted their price objective for the stock from $3.00 to $7.00 in a research note on Monday. HC Wainwright reissued a "buy" rating and set a $12.00 target price on shares of Amylyx Pharmaceuticals in a research report on Wednesday, March 5th. Two research analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $8.00.

Hedge Funds Weigh In On Amylyx Pharmaceuticals

Large investors have recently added to or reduced their stakes in the company. Blue Trust Inc. increased its position in shares of Amylyx Pharmaceuticals by 232.1% during the fourth quarter. Blue Trust Inc. now owns 6,987 shares of the company's stock valued at $26,000 after purchasing an additional 4,883 shares during the period. Fox Run Management L.L.C. bought a new stake in Amylyx Pharmaceuticals in the 4th quarter valued at $45,000. Alpine Global Management LLC acquired a new position in shares of Amylyx Pharmaceuticals in the 4th quarter valued at $45,000. RPO LLC bought a new position in shares of Amylyx Pharmaceuticals during the 4th quarter worth about $46,000. Finally, EntryPoint Capital LLC acquired a new stake in shares of Amylyx Pharmaceuticals during the 4th quarter valued at about $53,000. Institutional investors and hedge funds own 95.84% of the company's stock.

Amylyx Pharmaceuticals Company Profile

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.